Microfluidics: Rapid Diagnosis for Breast Cancer

Area of Science:

• Oncology
• Biomedical Engineering
• Medical Diagnostics

Background:

• Breast cancer is a leading cause of cancer diagnosis in women globally, affecting 1.7 million people in 2012.
• Current diagnostic methods rely on complex, expensive equipment, leading to accessibility issues, potential misdiagnosis, and delayed treatment.
• Genetic mutations, inherited or environmental, drive the uncontrollable cellular growth characteristic of breast cancer.

Purpose of the Study:

• To critically review the effectiveness and patient survival impact of current breast cancer diagnostic techniques.
• To present microfluidics biomarker detection as a novel, accessible alternative for breast cancer screening.
• To evaluate the potential of microfluidics for improving global breast cancer diagnosis and patient outcomes.

Main Methods:

• Literature review of existing breast cancer diagnostic technologies and their limitations.
• Analysis of diagnostic effectiveness concerning patient survival rates.
• Introduction and assessment of microfluidics-based biomarker detection as a primary screening tool.

Main Results:

• Current diagnostic equipment is often inaccessible, leading to underdiagnosis or overdiagnosis due to human error.
• Microfluidics biomarker detection offers a robust, high-throughput, low-energy, and accessible alternative.
• This microfluidics approach shows promise as an effective primary screening tool for breast cancer.

Conclusions:

• There is a critical need for improved, globally accessible breast cancer diagnostic tools.
• Microfluidics biomarker detection presents a viable solution to overcome the limitations of current methods.
• This technology has the potential to significantly enhance early breast cancer detection and improve patient survival worldwide.